Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease

Clinical Therapeutics

Volumn 26, Issue 7, 2004, Pages 980-990

  Finkel, Sanford I ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Il 60091 ^*  (United States)

Author keywords

Alzheimer's disease; behavior; cholinergic deficits; psychosis; rivastigmine

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; MICROSOME ENZYME; PLACEBO; PLASMA PROTEIN; PSYCHOTROPIC AGENT; RIVASTIGMINE;

AGGRESSIVENESS; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; APATHY; APPETITE DISORDER; ASTHENIA; ASTHMA; BEHAVIOR; CHOLINERGIC ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DELUSION; DEMENTIA; DISEASE PREDISPOSITION; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; EUPHORIA; HALLUCINATION; HUMAN; INSOMNIA; IRRITABILITY; LEWY BODY; LOCOMOTION; LOGISTIC REGRESSION ANALYSIS; MEDLINE; MENTAL DISEASE; NAUSEA; NEUROPSYCHIATRY; PSYCHOSIS; REVIEW; SEIZURE; SICK SINUS SYNDROME; SIDE EFFECT; SOMNOLENCE; URINE RETENTION; VOMITING;

EID: 4344668941     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90172-5     Document Type: Article

References (62)

1. Finkel S.I., Costa e Silva J., Cohen G., et al. Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 8:(Suppl 3):1996;497-500
2. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry. 15:(Suppl 1):2000;S2-S4
3. Rabins P.V., Lyketsos C.G., Steele C. Practical Dementia Care. 1999;Oxford University Press, New York
4. Lyketsos C.G., Steele C., Steinberg M. Neuropsychiatric symptoms in dementia. Gallo J.J., Busby-Whitehead J., Rabins P.V.,, et al. Care of the Elderly: Clinical Aspects of Aging. 5th ed. :1999;214-228 Williams & Wilkins, Baltimore
5. Rosenstein L.D. Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: A summary of the literature of the early 1990s. Neuropsychol Rev. 8:1998;109-167
6. Cummings J.L. Treatment of Alzheimer's disease. Clin Cornerstone. 3:2001;27-39
7. Lyketsos C.G., Lopez O., Jones B., et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the Cardiovascular Health Study. JAMA. 288:2002;1475-1483
8. Mortimer J.A., Ebbitt B., Jun S.P., Finch M.D. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology. 42:1992;1689-1696
9. Miller T.P., Tinkleberg J.R., Brooks J.O. III, et al. Selected psychiatric symptoms associated with rate of cognitive decline in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol. 6:1993;235-238
10. Lopez O.L., Wisniewski S.R., Becker J.T., et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 56:1999;1266-1272
11. Walsh J.S., Welch H.G., Larson E.B. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 113:1990;429-434
12. Mortiz D.J., Fox P.J., Luscombe F.A., Kraemer H.C. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 54:1997;878-885
13. Gurvich T., Cunningham J.A. Appropriate use of psychotropic drugs in nursing homes. Am Fam Physician. 61:2000;1437-1446
14. Working Group for the Royal College of Psychiatrists' Faculty of Old Age Psychiatry, British Geriatrics Society, Royal College of General Practitioners, Alzheimer's Society. Guidance for the management of behavioural and psychiatric symptoms in dementia and the treatment of psychosis in people with history of stroke/TIA following CSM restriction on risperidone and olanzapine. March 5, 2004;. Available at: http://www.bgs.org.uk/publication/ CSM%20announcement%2009%2003%202004.pdf. Accessed March 30, 2004
15. Ibach B., Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharm Des. 10:2004;231-251
16. Cummings J.L., Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology. 47:1996;876-883
17. Whitehouse P.J. Treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 5:(Suppl 1):1991;S32-S36
18. Geula C. Abnormalities of neural circuitry in Alzheimer's disease: Hippocampus and cortical cholinergic innervation. Neurology. 51:(Suppl 1):1998;S18-S29
19. Mesulam M.M., Mufson E.J. Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey. Brain. 107:1984;253-274
20. Levy M.L., Cummings J.L., Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology. 45:(Suppl 1):1999;15-22
21. Trinh N.H., Hoblyn J., Mohanty S., Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. JAMA. 289:2003;210-216
22. Mesulam M., Guillozet A., Shaw P., Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 9:2002;88-93
23. Clegg A., Bryant J., Nicholson T., et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review. Health Technol Assess. 5:2001;1-137
24. Doody R.S., Stevens J.C., Beck C., et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56:2001;1154-1166
25. Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's Disease. CNS Drugs. 12:1999;307-323
26. Greig N.H., Utsuki T., Yu Q., et al. A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase. Curr Med Res Opin. 17:2001;159-165
27. Ballard C.G. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition. Eur Neurol. 47:2002;64-70
28. Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 127:2002;6-19
29. Rösler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl. 127:2002;20-36
30. Darvesh S., Grantham D.L., Hopkins D.A. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol. 393:1998;374-390
31. Darvesh S., Hopkins D.A. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol. 463:2003;25-43
32. Rösler M., Klein H.E., Ackenheil M. An open study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia. Poster presented at: 41st Annual Meeting of the American College of Neuropsychopharmacology. December 8-12, 2002;. San Juan, Puerto Rico
33. Moretti R., Torre P., Antonello R.M., et al. An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia. Curr Ther Res Clin Exp. 63:2002;443-458
34. Reading P.J., Luce A.K., McKeith I.G. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord. 16:2001;1171-1174
35. Feldman H., Gauthier S., Hecker J., et al. Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 57:2001;613-620
36. Winblad B., Engedal K., Soininen H., et al. Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 57:2001;489-495
37. Prasher V.P., Huxley A., Haque M.S. Down Syndrome Ageing Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - pilot study. Int J Geriatr Psychiatry. 17:2002;270-278
38. Tariot P.N., Cummings J.L., Katz I.R., et al. A randomized double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 49:2001;1590-1599
39. Tariot P.N., Solomon P.R., Morris J.C., et al. Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 54:2000;2269-2276
40. Lane R., Tekin S., Mesenbrink P. The efficacy of rivastigmine on behavioral symptoms of activity disturbances in patients with Alzheimer's disease. Poster presented at: American Association for Geriatric Psychiatry Annual Meeting. March 1-4, 2003;. Honolulu, Hawaii
41. Lane R., Spiegel R., Tekin S., Quarg P. Effects of rivastigmine on disruptive behaviour associated with Alzheimer's disease. Poster presented at: 7th Annual Meeting of the European Federation of Neurological Societies. August 30-September 3, 2003;. Helsinki, Finland
42. Corey-Bloom J.F., Anand R., Veach J. ENA 713 B352 Study Group. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1:1998;55-65
43. Rösler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 318:1999;633-638
44. Schneider L.S., Anand R., Farlow M. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol. 1:(Suppl 1):1998;26-34
45. Rösler M., Retz W., Retz-Junginger P., Dennler H.J. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol. 11:1998;211-216
46. McKeith I., Del Ser T., Spano P., et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet. 356:2000;2031-2036
47. Cummings J.L. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry. 157:2000;4-15
48. Grace J., Daniel S., Stevens T., et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial. Int Psychogeriatr. 13:2001;199-205
49. Bullock R., Moulias R., Steinwachs K.C., et al. Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer's disease. Int Psychogeriatr. 13:(Suppl 2):2001;242. Abstract P248
50. Cummings J, Koumaras B, Rabinowicz A, et al. Effects of rivastigmine (Exelon®) treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe Alzheimer's disease. Am J Geriatr Psychiatry. In press.
51. Cummings J., Anand R., Koumaras B., et al. Rivastigmine treatment on the psychiatric and behavioral disturbances of nursing home residents with moderate to severe Alzheimer's disease (final results). Poster presented at: International Psychogeriatric Association. August 17-21, 2003;. Chicago, Ill.
52. Messina J., Koumaras B., Hartman R. Treatment with rivastigmine reduces the need for psychotropic medications in patients with Alzheimer's disease residing in long-term care facilities. Poster presented at: 3rd Annual International Meeting of the College of Psychiatric Neurological Pharmacists. April 6-9, 2000;. Washington, DC
53. Edwards K., Goodman W., Anand R., et al. Effect of Alzheimer's disease severity on psychotropic drug use and behavior in nursing home patients treated with rivastigmine. Poster presented at: 8th International Conference on Alzheimer's Disease and Related Disorders. July 17-22, 2002;. Stockholm, Sweden
54. Donepezil: Suspected adverse reactions. CMAJ. 159:1998;81
55. Donepezil: Suspected adverse reactions. CMAJ. 159:1998;85
56. Dunn N.R., Pearce G.L., Shakir S.A. Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol. 14:2000;406-408
57. Ito T., Yamadera H. The efficacy of donepezil in Alzheimer's disease. [in Japanese] J Nippon Med Sch. 69:2002;379-382
58. Wilkinson D., Doody R., Helme R., et al. Donepezil 308 Study Group. Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology. 61:2003;479-486
59. Exelon [package insert]. 2001;Novartis Pharmaceuticals Corporation, East Hanover, NJ
60. Sultzer D.L., Brown C.V., Mandelkern M.A., et al. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. Am J Psychiatry. 160:2003;341-349
61. Vennerica A., Shanks M.F., Staff R.T., et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. NeuroReport. 13:2002;83-87
62. Rombouts S.A., Barkhof F., Van Meel C.S., Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 73:2002;665-671